Note 9 - Commitments and Contingencies (Details Textual) - USD ($) $ / shares in Units, $ in Thousands |
6 Months Ended | |||
|---|---|---|---|---|
Mar. 14, 2017 |
Feb. 02, 2015 |
Jun. 30, 2017 |
Jun. 30, 2016 |
|
| Operating Leases, Rent Expense, Net | $ 95 | $ 54 | ||
| Research and Development Expenses Settled by Shares Issuance | $ 42,259 | |||
| Shares Issued, Price Per Share | $ 20 | |||
| Private Placement [Member] | Nereus Trust [Member] | ||||
| Stock Issued in Lieu of Royalty Payments | 2,112,963 | |||
| Wanchun Biotech [Member] | ||||
| Quarterly Royalty Payments Required As a Percentage of Gross Proceeds on Sale of Product | 20.00% | |||
| Term of Royalty Payments | 10 years | |||
| Wanchun Biotech and Fortis Advisors LLC [Member] | ||||
| Period Following Royalty Termination Agreement, Requirement to Issue Shares | 3 years | |||
| Percentage of Fully-diluted Equity Capitalization Required to Be Issued As Shares in Lieu of Royalty Payments | 10.00% | |||